✦ LIBER ✦

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

✍ Scribed by Mark A. Dickson; Manish A. Shah; Dana Rathkopf; Archie Tse; Richard D. Carvajal; Nian Wu; Robert A. Lefkowitz; Mithat Gonen; Lauren M. Cane; Heather J. Dials; Gary K. Schwartz

Book ID: 105993398
Publisher: Springer
Year: 2010
Tongue: English
Weight: 392 KB
Volume: 66
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1269-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical and pharmacokinetic tri

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

✍ James P. Thomas; Kendra D. Tutsch; James F. Cleary; Howard H. Bailey; Rhoda Arzo 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 252 KB

A first-in-man phase I tolerability and

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

✍ D. Ross Camidge; Dominic Smethurst; Jim Growcott; Nigel C. Barrass; John R. Fost 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 324 KB

A phase I trial of the selective oral cy

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

✍ Benson, C; White, J; Bono, J De; O'Donnell, A; Raynaud, F; Cruickshank, C; McGra 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

A phase I clinical and pharmacokinetic s

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

✍ R. O’Connor; M. O’Leary; J. Ballot; C. D. Collins; P. Kinsella; D. E. Mager; R. 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 291 KB

Clinical trial: evaluation of gastric ac

Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers

✍ P. Miner Jr; J. Plachetka; E. Orlemans; J. G. Fort; M. Sostek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB